Donor leukocyte infusions (DLI) have turned out to be an efficient way to re-establish complete remission (CR) in chronic myeloid leukemia (CML) patients relapsing after allogeneic bone marrow transplantation (BMT). In these patients, absence of PCR bcr-abl fusion transcripts confirmed the potency of donor leukocytes to induce molecular response in relapsed CML. This ensured sustained remission and long-term survival. In this study, the capacity of DLI to induce molecular remission in acute leukemia relapse after BMT was analyzed. The results showed that following DLI, leukemic cell eradication gradually occurred over a prolonged time period. The time to complete disappearance of the molecular marker of the disease was 30 weeks in RT-PCR analysis. A sustained and persistent elimination of an AML1/ETO-positive leukemic clone in an AML-M 2 patient was observed. In contrast, an AML-M 5 with t(11;19) and an E2A/PBX1-positive ALL achieving cytogenetic and molecular bone marrow CR developed following DLI unusual sites of extramedullary leukemia relapse, despite continued bone marrow remission. This study adds further proof of the benefit of donor cell therapy in acute leukemia but shows that complete leukemic cell eradication appears to require a critical interval in order to establish effective immune responses at all sites where leukemic cells persist.
Introduction
Insufficient or no graft-versus-leukemia (GVL) effect after allogeneic bone marrow transplantation (BMT) can lead to disease recurrence, especially in high-risk leukemias. [1] [2] [3] [4] In cases of leukemia relapse, hope of a cure is dramatically reduced. Nevertheless, long-term survival has been obtained in leukemia relapse post-transplant by the induction in the recipient of a GVL activity using donor leucocyte infusions (DLI). 5 This procedure has proved its efficiency in recurrences of chronic myeloid leukemia (CML) after allogeneic BMT. 6 Response to donor leukocytes was associated with complete disappearance of the bcr-abl fusion transcript, ensuring sustained remission and long-term survival. 7 In acute leukemia relapse, results from several large analyses indicate that 24-39% of patients may achieve remission after immunoadoptive therapy. [7] [8] [9] [10] Among the complete remitters, the capacity of such a strategy to induce molecular remission is not well-established. In order to clarify this question, high-risk recurring acute leukemias were analyzed in this study by RT-PCR technology for molecular response to donor cell therapy. The results showed that an efficient and durable anti-leukemic response could be obtained using DLI in acute leukemia relapse post-transplant. The molecular response to donor leukocytes gradually occurred over an extended period of about 6 months. However, two patients developed unexpected extramedullar leukemic relapses after the therapy. This conCorrespondence: C Berthou; Fax: 33 298 22 39 81 Received 22 January 1998; accepted 11 June 1998 trasted with continued bone marrow remission. Such complications were not explained by the emergence of new tumoral clones as shown by molecular analysis of leukemic cells isolated from the extramedullar sites. Our data suggested that the anti-leukemic effect of donor leukocytes was limited to medullar sites.
Patients, materials and methods

Patient characteristics
Three patients with clinically relapsed acute leukemia were analyzed (Table 1) . Their leukemic cells contained specific gene or chromosomal rearrangements detectable by RT-PCR or FISH analysis. All patients received bone marrow grafts from an HLA-identical sibling. Graft-versus-host disease (GVHD) prophylaxis after allogeneic BMT consisted of a combination of short-course methotrexate and standard-dose cyclosporin A. All patients experienced grade 0 GVHD and no chronic GVHD was diagnosed after BMT. In relapse posttransplant, they received one course of chemotherapy consisting of a combination of cytosine arabinoside 1 g/m 2 intravenously every 12 h for eight doses, daunorubicin 50 mg/m 2 and mitoxantrone 12 mg/m 2 each for two doses. This regimen was associated with G-CSF support starting on day +14 of the chemotherapy.
Immunoadoptive therapy with DLI
When a complete remission (CR) was obtained, DLI were immediately carried out. Peripheral blood mononuclear cells were collected by leukapheresis of the patient's original bone marrow donor. They were collected using an apheresis system (Cobe Spectra; Cobe, Lakewood, CO, USA). Donor cells were freshly administered after each collection and were infused in four doses at 1-week intervals. At the time of DLI, no patient had GVHD and no prophylactic immunosuppression was given to any patient. All patients had an Eastern Cooperative Oncology Group performance status of 0-1.
Detection of abnormal fusion transcripts
Total RNA was extracted from 5 × 10 6 mononuclear cells from peripheral blood, bone marrow and tumoral tissues. 11 RT-PCR detection of E2A/PBX1 fusion transcripts was performed with two rounds of c-DNA amplification using two sets of commercially available oligonucleotide primers from the kit 'pre-B primer set' from Oncogene Science (Uniondale, NY, USA). 12, 13 It included control primers for detection of the normal E2A mRNA. Final sensitivity was 10 −5 . The cell line IARC-318 was used as positive control and HL60 cells as negative controls. RT-PCR detection of AML1/ETO fusion transcripts was performed according to previously described methods.
14,15 A semi-nested second amplification was used to confirm the identity of amplified fragments with a final sensitivity of 10 . Positive (another patient) and negative (HL60 cells) controls were included in each experiment. ABL transcripts were analyzed to assess the quality of RNA extracts. All amplifications were performed using a thermocycler from Hybaid (Teddington, UK).
Cytogenetic and FISH analysis of leukemic cells
Cytogenetic investigations were performed using bone marrow and/or peripheral blood samples, after 24 and 48 h of culture. Some were fluorodeoxyuridine (FUDR) synchronized 16 and chromosome preparations were made by conventional techniques with reverse heat Giemsa (RHG) banding. 17 The results were expressed according to the International System for Human Cytogenetic Nomenclature (ISCN 1995). 18 FISH studies (metaphase and interphase) were carried out for case 1 on bone marrow leukemic cells and for case 3 on blood, bone marrow, pleural and peritoneal cells. The slide preparations, stored at −25°C were prepared with 1 mg/ml RNAase for 45 min. Chromosomal DNA was denatured in 70% formamide, 2 × SSC, pH 7.3, at 70°C for 3 min. FISH was performed with whole chromosome paint probes (WCP 8 and WCP 11, Cambio, Cambridge, UK), a chromosome 8 specific centromere probe (CEP 8, Vysis, Downers Grove, IL, USA), the CEP X probe and the Oncor MLL (11q23) DNA probe for detecting rearrangements at the MLL locus. Probes were denatured according to the manufacturer's instructions. The detection protocol used the S1331-DF and S1333-BF kits from Oncor (Gaithersburg, MD, USA). For our experiments, only the signal from the MLL gene was amplified. The three different probes were detected with fluorescein (green signal) with a final sensitivity of 10 −1
. Metaphase and interphase cells were mounted in antifade medium containing DAPI and propidium iodide. The slides were examined with a Leica DMRB epifluorescence microscope (HBO 100 lamp), a motorized filter wheel (Ludl Electronic Products, model 23 E -6102A, USA) fitted with a Chroma Filters Pinkel Set. The FISH image capture was done with a Hamamatsu chilled camera type C5985 and driver type C6391 coupled with a ISIS3 Meta Systems analyzer (Altuslheim, Germany).
Results
Case 1
This patient developed an AML FAB-M 2 associated with a chromosomal translocation t(8;21)(q22;q22) and received an allogeneic BMT in first CR from an HLA-identical sister. Complete chimerism was obtained. Two years later, bone marrow relapse occurred. Blast cells displayed an identical translocation t(8;21)(q22;q22) associated with the loss of one chromosome X in 88% of clonal cells (FISH analysis). The AML1/ETO fusion transcript was detected in leukemic cells ( Figure 1, lanes 2 and 10) . Following chemotherapy-induced second CR, the AML1/ETO fusion transcript remained easily detectable in peripheral blood and bone marrow cells, after the first round RT-PCR (Figure 1, lanes 3 and 11) . DLI were then performed, using 4.3 × 10 8 /kg mononuclear cells (3.1 × 10 8 /kg T lymphocytes) ( Table 2 ). The results of the RT-PCR studies subsequently performed at 3-month intervals are shown in Figure 1 . On the initial PCR study following donor cell therapy, a peripheral blood sample was weakly positive at the first round and clearly positive at the second round ( Figure 1, lanes 4 and 12) . Three months later, a peripheral blood sample was weakly positive but only after the second round ( Figure 1, lanes 5 and 13) . At week +30 following initial donor cell infusion, the leukemic transcript became totally undetectable, there was still no detection after the second round PCR (Figure 1, lanes 6 and 14) . No detection of the fusion transcript was confirmed in four subsequent experiments performed at 3-month intervals. Following DLI, a transient mild hepatic GVHD appeared and a continued mucous c-GVHD is still observed which is not opposed by immunosuppression.
Case 2
An 18-month-old boy suffered from an early pre-B cell CD10 + ALL. Leukemic blasts contained a chromosomal translocation t(I;19)(q23;p13). Because of an early bone marrow relapse (18 months after first CR), the child received an allograft in second CR from an HLA-identical brother. Six months after transplant, a second medullary relapse occurred. The translocation t(I;19)(q23;p13) was still present in recipient-type lymphoblasts. The cells also contained the typical E2A/PBX1 fusion 
Figure 3
Interphase FISH study performed on peritoneal infiltrating monoblasts isolated from case 3, using the chromosome 8 specific centromere probe (CEP 8). The probe detected pentasomy of chromosome 8 in a large fraction (73%) of leukemic cells. 
Case 3
An AML FAB-M 5a occurred in a 45-year-old female. Leukemic cells contained a chromosomal translocation t(11;19) (q23;p13) associated with pentasomy of chromosome 8. This high-risk leukemia imposed an allogeneic BMT from an HLAidentical brother in first CR. Three months after graft, bone marrow relapse was obvious. DLI were performed after chemotherapy, using 11.4 × 10 8 /kg mononuclear cells (7.1 × 10 8 /kg T lymphocytes) ( Table 2 ). This was followed by a grade 3 cutaneous and hepatic GVHD, requiring corticosteroid and cyclosporin A therapy. On treatment of GVHD, extramedullary sites of relapse developed in serous membranes. Pericardial and pleural effusions were analyzed for infiltrating monoblasts: a large fraction (66%) of these femaletype leukemic cells had pentasomy of chromosome 8 and all contained the chromosomal translocation t(11;19) ( Table 3) . A simultaneous study of interphasic bone marrow cells using the CEP 8 probe failed to detect any leukemic progenitor cells (Table 3) , while complete chimerism was demonstrated by cytogenetic analysis. Corticotherapy was ended and a new chemotherapy treatment began. A third CR was obtained. Despite a continued skin scleroderma-like c-GVHD, relapse occurred in the peritoneum. In the ascitic female-type monoblasts, predominant (73%) pentasomic cells for the chromosome 8 were present (Figure 3 ) (Table 3) .
Discussion
The benefit of further therapy on survival of acute leukemia patients relapsing after allogeneic BMT has been recently analyzed. 9 The results favored immunotherapy because of better tolerance compared to conventional second allografts and also with regard to its applicability to a greater number of patients. Analysis of published results shows that adoptive immunotherapy used alone for treatment of full hematological relapse of acute leukemia leads to 15% (13/84) of complete remission. 7, 8, [19] [20] [21] [22] [23] [24] However, in order to control the disease in acute leukemia relapses, a combination of chemotherapy and immunotherapy is now increasingly used. According to the literature, this strategy allows 55% of disease-free survival (19/34) , with a median follow-up of 330 days (range from 40 to 780 days). 7, 8, 19, 20, [25] [26] [27] [28] [29] Such results of donor cell therapy in acute leukemia compared unfavorably with those obtained for cytogenetic or Table 3 FISH studies performed on bone marrow cells from case 3 at various time intervals after DLI and on monoblasts obtained from extramedullary sites, using CEP 8 probe (% of positive cells/500 cells analyzed) hematologic relapse of CML, where complete and durable molecular remission could be induced in 73-76% of cases. 7, 8 The difference in the rate of remission induction suggests that CML might represent a more suitable candidate for immunoadoptive therapy, which could be related to the expression of a unique chimeric protein resulting from the chromosomal translocation. 30 In CML, complete cytogenetic responses to DLI were shown to be achieved in a median of 4 months, but molecular remission with the absence of bcr/abl fusion transcripts as determined by RT-PCR may require several months. 31 In acute leukemias, immunogenicity of clonal cells is probably more uncertain due to heterogenous genetic rearrangements observed therein. In addition, the capacity of donor leukocytes to completely eliminate expression of fusion transcripts in responders needs further evaluation.
We used a combination of chemotherapy and DLI in the treatment of three acute leukemias relapsing after BMT. Close RT-PCR monitoring of minimal residual disease was performed in two patients expressing E2A/PBX1 and AML1/ETO fusion transcripts. We observed a gradual disappearance of the specific molecular marker of the disease in an interval of 6 to 7 months. This result suggested that molecular remission induction was independent of pretreatment with cytoreductive drugs and was in fact due to the delayed anti-leukemic activity of the infused donor cells. According to the highly sensitive method of minimal residual disease detection used, residual leukemic progenitor cells represented less than 1/10 5 cells following the adoptive therapy. Elimination of leukemic cells during this extended time period could reflect the requirement for specific T cell proliferation and expansion and implies that leukemic eradication may not occur rapidly. The significance of achieving such a complete molecular remission in acute leukemia after allogeneic cell therapy has been previously questioned. A persistent AML1/ETO fusion transcript after allo-geneic BMT was shown to be compatible with continued CR. 32, 33 However, other data emphasized that patients not achieving a molecular remission after BMT could suffer from a higher rate of leukemic relapse compared to those with a negative RT-PCR test. [34] [35] [36] We and others 24 have shown that eliminated expression of AML1/ETO fusion transcripts after DLI was associated with a sustained and persistent complete molecular remission. The efficiency of inducing an anti-leukemic effect by DLI in t(8;21) AML relapse post-graft could be related to immunogenicity of peptide(s) derived from the fusion protein created by the leukemia-specific chromosomal translocation.
Potential extramedullary relapse occurrence after immunoadoptive therapy is now a well-established problem for this strategy. In this study, unexpected extramedullar sites of leukemia relapse occurred in a t(1;19) ALL and a t(11;19) AML, more than 1 year after initial immune therapy. Molecular studies performed on the leukemic cells isolated from these extramedullary sites of relapse revealed identical genetic rearrangements as found in first bone marrow analysis. Despite extramedullary recurrence of the disease, the continued hematological remission we and some others 28, 29, 37 observed after DLI favored a relatively specific activity of activated donor T cells inside the hematopoietic tissue. These observations further suggested that recruitment of activated cytotoxic lymphocytes in all leukemia-containing organs was not fully operative or was delayed. Lymphocyte activation occurring in the marrow or spleen most likely led to the expression of lymphocyte surface molecules directing selective homing only to those tissues. 38 In addition, down-regulation of critical cell surface molecules such as the Fas antigen [39] [40] [41] and/or induced expression of membrane Fas ligand could enable the leukemic cells in extramedullar sites to reduce their susceptibility to the cytotoxic lymphocyte attack. Tumoral cells and cell lines have recently been shown to express functional Fas ligand and to kill T cells in a Fas-mediated manner. This could explain in vivo protection of the tumoral tissue from the immune system. 42, 43 Furthermore, recruitment of accessory cells necessary to achieve an efficient local anti-leukemic activity as recently shown in mice, 44 may be lacking or deficient in extramedullar sites of leukemic relapse. Obviously, complete leukemic cell eradication appears to require an adequate time to establish effective cytotoxic cell responses at all sites where leukemic cells persist.
Analysis of the molecular response to donor cell therapy in acute leukemia further confirmed that the expected antileukemic effect of donor mononuclear cells did occur in this disease. However, better results of this form of salvage therapy could be expected by optimizing the chemotherapy and restoring leukemia immunogenicity in vivo by the combined use of DLI and cytokines. Furthermore, as GVHD treatment affects GVL, determination of the level of acceptance of the GVHD after donor leukocyte transfusions before setting up an immunosuppression plan and selecting suitable immunosuppressive drugs is also of concern. In the near future, the area of vaccination will constitute an efficient way for expansion of specific anti-tumor T cell lytic activity but it is now in its early stages in humans. 45 
